Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis

[1]  Giuseppe Lippi,et al.  Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States , 2020, Diagnosis.

[2]  Nathaniel Hupert,et al.  Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.

[3]  Xin Li,et al.  COVID-19 with Different Severities: A Multicenter Study of Clinical Features , 2020, American journal of respiratory and critical care medicine.

[4]  Yongsheng Li,et al.  Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19 , 2020, American journal of respiratory and critical care medicine.

[5]  Mohammad Madjid,et al.  Potential Effects of Coronaviruses on the Cardiovascular System: A Review. , 2020, JAMA cardiology.

[6]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[7]  Y. Xiong,et al.  Clinical features and treatment of COVID‐19 patients in northeast Chongqing , 2020, Journal of medical virology.

[8]  Wei Liu,et al.  Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study , 2020, Chinese medical journal.

[9]  Giuseppe Biondi-Zoccai,et al.  Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic , 2020, Journal of the American College of Cardiology.

[10]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[11]  Bo Li,et al.  Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China , 2020, Clinical Research in Cardiology.

[12]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[13]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[14]  W. Tang,et al.  Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. , 2020, European review for medical and pharmacological sciences.

[15]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[16]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[17]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[18]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Jing Yuan,et al.  Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury , 2020, Science China Life Sciences.

[20]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[21]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[22]  D. Brodie,et al.  Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic , 2020 .

[23]  A. Torres,et al.  Early, short and long-term mortality in community-acquired pneumonia , 2018 .

[24]  Gurkirpal Singh,et al.  Interleukin 6 Inhibition and Coronary Artery Disease in a High‐Risk Population: A Prospective Community‐Based Clinical Study , 2017, Journal of the American Heart Association.

[25]  J. Delfraissy,et al.  Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in Cambodia , 2016, PloS one.

[26]  A. Garg,et al.  Macrolide antibiotics and the risk of ventricular arrhythmia in older adults , 2016, Canadian Medical Association Journal.

[27]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[28]  P. Stas,et al.  Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. , 2008, International journal of cardiology.

[29]  T. Nolin,et al.  Antimicrobial-associated QT interval prolongation: pointes of interest. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  J. Dhainaut,et al.  Underlying disorders and their impact on the host response to infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .